Breath of change: Cystic Fibrosis Australia forges pioneering partnership with local medtech

MedTech & Diagnostics News: In a move aimed at enhancing cystic fibrosis (CF) care and support, Australian-based medical device company, Bird Healthcare, has announced its collaboration with Cystic Fibrosis Australia (CFA).

Cystic fibrosis, a complex condition requiring extensive medical care, therapies, and unwavering support, poses significant challenges for patients and their families. This strategic alliance aims to drive positive change by focusing on improving CF management and outcomes, ultimately striving for a better quality of life for those impacted by this condition.

“This presents a highly promising prospect, and I eagerly anticipate a close working relationship with the team,” expressed Jo Armstrong, CEO of Cystic Fibrosis Australia. “Establishing national corporate partnerships, such as this one, is essential for effectively tackling the major challenges affecting all Australians living with cystic fibrosis.”

Tim Boult, Director of Bird Healthcare, expressed genuine enthusiasm for the collaboration’s potential to create positive outcomes.

“Through our partnership with Cystic Fibrosis Australia, we are confident that we can make a real difference in improving the lives of CF patients and their families. We invite everyone to join us in celebrating this important milestone and supporting the ongoing efforts to raise awareness and financial support for cystic fibrosis,” he stated.

This partnership goes beyond mere collaboration. Bird Healthcare pledges a portion of its profits from their CF range of medical devices to contribute to CFA’s indispensable work in funding research initiatives, advocating for policy changes, and striving for optimal outcomes for Australians living with cystic fibrosis.

The Health Industry Hub^TM content is copyright protected. Access is available under individual user licenses. Please click here to subscribe and visit T&Cs here.